Chronic Myeloid Leukemia

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

By

EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.

Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries

Generic Imatinib Compared With Gleevec in CP-CML: Patient Outcomes Across 3 Countries

By

Although the study suggested the efficacy of the branded version was superior to its generic counterpart, more research may be necessary to tease out manufacturer differences.

Second-Generation TKIs in Advanced CML: 7-Year Survival Rates

Second-Generation TKIs in Advanced CML: 7-Year Survival Rates

By

In patients who have been newly diagnosed with AP-CML, the initiation of TKI2 therapies in the frontline setting provided excellent responses and survival rates.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Prototype Intervention Increased Adherence to TKIs in CML

Prototype Intervention Increased Adherence to TKIs in CML

By

A prototype intervention increased adherence to tyrosine kinase inhibitor therapy in some patients with chronic myeloid leukemia.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML

By

The majority of patients studied who stopped TKI therapy remained treatment-free at 3 years.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia

Imatinib Determined the Most Cost-Effective Frontline TKI for Chronic Myeloid Leukemia

By

Cost-effectiveness of TKIs for CML treatment is a complex topic that requires consideration of multiple factors — not just apparent costs to payers.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia

Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia

By

A new method for rapid, ultrasensitive detection of BCR-ABL1 mRNA in chronic myeloid leukemia was described; the tool may have diagnostic utility.

New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro

New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro

By

The addition of AR-42 to imatinib yielded synergistic activity in chronic myeloid leukemia cells and also appeared to reverse therapeutic resistance.

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis

Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis

By

A matching-adjusted indirect comparison concluded that ponatinib offers better disease control compared with bosutinib in certain patients.

Dasatinib in Chronic Myeloid Leukemia Linked to Higher Health Care Costs

Dasatinib in Chronic Myeloid Leukemia Linked to Higher Health Care Costs

By

Increased costs were found to be a result of more infections.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Pleural Effusions More Common Than Previously Thought in Dasatinib-Treated Leukemias

Pleural Effusions More Common Than Previously Thought in Dasatinib-Treated Leukemias

By

With newer treatments, alternatives to dasatinib exist, if needed.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

By

For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

By

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

By

Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

By

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

By

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Time of Response to TKI Therapies May Influence Patient Outcomes in CML

Time of Response to TKI Therapies May Influence Patient Outcomes in CML

By

Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

By

There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.

The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

By

Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patients.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

By

A large, long-term study found a 97% event-free survival rate at 18 months.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs